Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.79 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.61 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4389390 | 0.93 | PDE10A (0.70) | PDE10AMCHR1HDAC1HDAC2NQO2 | |
| SCHEMBL18682211 | 0.91 | PDE10A (0.68) | PDE10AMCHR1 | |
| SCHEMBL7509842 | 0.89 | PDE10A (1.00) | PDE10AMCHR1 | |
| SCHEMBL2840650 | 0.87 | PDE10A (0.63) | PDE10AMCHR1HDAC1HDAC2NQO2 | |
| SCHEMBL18668570 | 0.87 | PDE10A (0.63) | PDE10AMCHR1 | |
| SCHEMBL23366133 | 0.87 | PDE10A (0.63) | PDE10AMCHR1DHFRHDAC1HDAC2 | |
| SCHEMBL5928336 | 0.86 | PDE10A (0.62) | PDE10AMCHR1HDAC1HDAC2 | |
| SCHEMBL5928050 | 0.86 | PDE10A (0.62) | PDE10AMCHR1DHFRHDAC1HDAC2 | |
| SCHEMBL16151253 | 0.86 | PDE10A (0.62) | PDE10AMCHR1 | |
| SCHEMBL7453345 | 0.86 | PDE10A (0.61) | PDE10AMCHR1HDAC1HDAC2NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | claimed |
| US-8324196-B2 | Polyquinoline derivatives and the therapeutic use thereof | PALUMED S.A. (FR) | 2012-12-04 | — | — | US | disclosed |
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-11-01 | — | — | US | disclosed |
| US-8247396-B2 | Polyquinoline derivatives and therapeutic use thereof | PALUMED S.A. (FR) | 2012-08-21 | — | — | US | disclosed |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | HTT, APP, PSEN1 | PDE10A 2625/4885MCHR1 3521/4885DHFR 3469/4885 |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | HTT, UBQLN2, UBQLN1 | PDE10A 1162/4885MCHR1 3156/4885DHFR 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.